Board

The Board of Directors comprises a Non-Executive Chairman, John “Jack” Cashman, three Non-Executive Directors, Dr Andrew Richards, Dr Susan Foden and Dr John Brown and two Executive Directors, Dr Christopher Blackwell, Chief Executive Officer and Anne Hyland, Chief Financial Officer and Company Secretary.

John P "Jack" Cashman Non-Executive Chairman

Jack Cashman joined the Board of Vectura as Non-Executive Chairman in 2001. Mr. Cashman brings significant experience to the Board of Vectura, having held a variety of senior executive level roles in business and as a Board member for several companies in both North America and Europe. He is currently Non-Executive Chairman of Interface Biologics Inc, a private Canadian therapeutic biomaterials company and Insception Biosciences Inc, Canada's largest and most established cord blood bank. He is also a Non-Executive Director of Phoqus Group plc, a UK company specialising in oral drug delivery, a Director of Transat AT Inc. (Canada), an integrated vacation company and a Director of Telesat Inc. (Canada), a satellite company.

Jack is the former Chairman and joint-Chief Executive Officer of RP Scherer Corporation and participated in its leveraged buyout and privatisation and its subsequent successful public offering flotation on the New York Stock Exchange. (RP Scherer was later acquired by Cardinal Health Inc). His early career was spent in the field of filtration and industrial mineral products. During that time, he took on successively more senior roles in marketing, operations and general management in the UK, Europe, Canada and USA. With this experience, he decided to pursue an entrepreneurial career in the industrial and healthcare sectors.

Andrew J M Richards, BA, MA (Cantab), MSc, PhD, CChem Non-Executive Director

Andy Richards joined the Board of Vectura as a Non-Executive Director in 2000. He is an established biotechnology entrepreneur and business angel, focusing on founding, investing in, and assisting in the development of biotechnology and healthcare companies. He has broad experience of the UK biotechnology sector in research, drug development and in building commercial relationships.

He is Chairman of Altacor Ltd, and a Non-Executive Director of Aitua Ltd, Biowisdom Ltd, Babraham Bioscience Technology Ltd, Cancer Research Technology Ltd (the commercial arm of Cancer Research UK), Pharmakodex Ltd, Theradeas Ltd and VASTox plc. He is also a founder member of the Cambridge Angels, and a director of the BIA (BioIndustry Association).

In 1992, he co-founded Chiroscience and was Business Development Director through to its merger in 1999 with Celltech. Originally a protein chemist, Andy spent his early career with ICI (now AstraZeneca) and with PA Technology.

John R Brown, BSc, PhD, MBA, FRSE Non-Executive Director

John Brown joined the Board of Vectura as Non-Executive Director and Senior Independent Director in 2004. He currently chairs the Governing Council of the Roslin Institute in Edinburgh and is Chairman of Scottish Biomedical. He is a Non-Executive Director of a number of private and public biotech companies including Ardana plc and Protherics plc. He sits on the Advisory Board of the Life Sciences ITI in Scotland and is a member of the DTI Technology Strategy Board. He is also Chairman of BIA Scotland.

Until December 2003, John was Chief Executive of the FTSE 250 biotech company Acambis plc, a leading producer of vaccines to treat and prevent infectious disease. He joined Acambis as Finance Director in 1995 and was appointed CEO in 1997.

Prior to Acambis he worked in equity research as Head of Research at Sutherland and Partners. John also worked at PA Consulting, where he advised both biotech and pharmaceutical companies. He previously spent five years at Glaxo Group Research where he led a group developing neuropeptide antagonists. John holds an MBA and a PhD in neuropharmacology.

Susan E Foden MA, DPhil Non-Executive Director

Susan Foden joined the Board of Vectura as a Non-Executive Director in January 2007 having previously served on the Board of Innovata plc. She holds a number of Non-Executive Directorships with both public and private companies and public funding bodies in the biotech and healthcare field, including Medical Solutions plc, PIramed Ltd, and Cell Centric Ltd, and she is a Trustee of The Institute of Cancer Research. Prior to this Susan held positions in venture capitalism, technology transfer and UK biotech. From 2000 to 2003, she was an Investor Director with the London-based venture capital firm Merlin Biosciences Limited and was Chief Executive Officer of the technology transfer company, Cancer Research Campaign Technology Limited, from 1997 to 2000.

From 1983 to 1987 Susan headed up the academic liaison function at what was then Celltech Limited, dealing with some of the earliest tech transfer deals in the UK, which set industry precedents. She studied biochemistry at the University of Oxford from where she obtained an MA and a DPhil.

Christopher Blackwell, BSc, PhD Chief Executive and Executive Director

Chris Blackwell was appointed Chief Executive of Vectura in February 2004. He joined the company in 2002 as Chief Operations Officer and Executive Director. Prior to Vectura he was Director of Drug Development and an Executive Director at Scotia Pharmaceuticals Ltd, which he joined in 1998. He was previously at Hoffman La-Roche specialising in project management, where he became UK Director, Global Project Management in 1996, and Glaxo Research and Development as a Clinical Pharmacologist.

Chris trained as a research scientist at the University of Bath, where in 1988 he completed his doctorate investigating free radicals and reperfusion-induced arrhythmias.

In July 2006 Chris was appointed Non-Executive Director of AGI Therapeutics plc, a speciality pharmaceutical company focused on gastrointestinal drug products.

Anne P Hyland, BBS, FCA, FITI Chief Financial Officer, Company Secretary and Executive Director

Anne Hyland was appointed Chief Financial Officer, Company Secretary and Executive Director of Vectura in March 2002. Prior to this, she was a Director of Corporate Finance at Celltech Group plc. Other positions held at Celltech included Group Financial Controller and Finance Director for the Celltech/Medeva UK Division. She joined Celltech following the merger with Medeva plc, where she was Finance Director for the UK Division. Previously, she was the Medeva Group Financial Controller where, through a period of rapid growth, she was responsible for managing treasury, tax, internal and external reporting, and acquisition and disposal activity.

Anne joined Medeva from KPMG, London, where she was an audit manager and gained exposure to corporate finance, advisory and due diligence work.

She has a Business Studies degree from Trinity College, Dublin, and is a Fellow of the Institute of Chartered Accountants, Ireland and a Fellow of the Institute of Taxation, Ireland.